Table 1.

Patient demographics and comorbidities by gastric acid suppression use

Characteristic	Gastric Acid Suppression Medication Use
	H2RA	PPI	Neither
	(n=1382)	(n=6020)	(n=16,395)
Demographics
Age, yr	61±15	62±14	59±15
Sex (% male)	53%	55%	58%
Race (% US Black)	22%	22%	24%
PD vintage, yr	0.4 (0.2 to 1.6)	0.6 (0.2 to 2.0)	0.4 (0.2 to 1.5)
ESKD vintage, yr	1.1 (0.3 to 2.9)	1.3 (0.4 to 3.1)	0.9 (0.3 to 2.4)
Comorbidity history
Diabetes	45%	48%	44%
Hypertension	86%	91%	90%
Coronary artery disease	23%	28%	14%
Heart failure	15%	19%	11%
Cerebrovascular disease	13%	13%	8%
Peripheral vascular disease	16%	13%	8%
Other cardiovascular diseases	17%	18%	10%
Lung disease	6%	6%	3%
Neurologic disease	4%	5%	3%
Psychiatric disorder	13%	11%	6%
Cancer	10%	10%	7%
Recurrent cellulitis/gangrene	2%	2%	0.9%
HIV	0.6%	1%	2%
GI comorbiditya	5%	7%	5%
Dialysis treatments
APD	80%	72%	72%
Assisted PD	18%	28%	28%
Laboratory/biometric markers
Body mass index, kg/m2	28.5±6.6	27.8±6.5	27.7±6.5
Serum albumin, g/dl	3.6±0.5	3.4±0.5	3.6±0.5
Hemoglobin, g/dl	10.9±1.6	10.9±1.6	10.9±1.6
Serum phosphorus, mg/dl	5.3±1.6	5.1±1.6	5.4±1.7
Serum calcium, mg/dl	8.9±0.8	8.7±0.8	8.8±0.8
Serum magnesium, mg/dl	2.2±0.5	2.1±0.5	2.2±0.5
Serum potassium, mEq/L	4.2±0.6	4.2±0.7	4.2±0.7
24-h urine volume, L	0.9±0.8	0.8±0.7	0.9±0.8
Medication use
Antiplatelet	48%	47%	34%
Aspirin	41%	41%	30%
Clopidogrel	11%	12%	6%
P2Y platelet inhibitors	6%	5%	3%

APD, automated peritoneal dialysis; GI, gastrointestinal; H2RA, histamine 2 receptor antagonist; PD, peritoneal dialysis; PPI, proton pump inhibitor.

^aGI comorbidity including liver disease, GI bleeding, GI cancer, hepatitis B and hepatitis C.